Neoadjuvant Nivolumab/Ipilimumab Outperforms Adjuvant Anti-PD-1 Therapy in Stage III Resectable Melanoma
Recent research showed neoadjuvant therapy with 2 cycles of nivolumab/ipilimumab outperformed 12 courses of adjuvant nivolumab in stage III resectable melanoma. ...
